The FDA told AstraZeneca and other companies to change their labels to warn about possible vision loss from GLP-1 drugs.

AZN · AstraZeneca

The AI's read

The warning raises concern because NAION can cause permanent vision loss. But the condition is rare, and analysts say the label change is unlikely to significantly affect sales. Together, these facts do not point to a clear change in AstraZeneca’s outlook.